COVID-19 in B Cell-Depleted Patients After Rituximab: A Diagnostic and Therapeutic Challenge리툭시 맙 후 B 세포 고갈 된 환자의 Covid-19 : 진단 및 치료 문제Review Published on 2021-11-032022-08-31 Journal: Frontiers in Immunology [Category] MERS, SARS, 바이오마커, 진단, [키워드] adaptive Adaptive immunity Affect anti-CD20 anti-CD20 therapy anti-CD20 treatment anti-SARS-CoV-2 anti-SARS-CoV-2 monoclonal antibodies Antiviral treatment association Autoimmune disorders B cell B cell immunodeficiency B cell-depletion challenge Course COVID-19 deficiencies diagnostics disease Effect exposure to function hematologic hyperimmune convalescent plasma immune Immunity Immunotherapy Impact Interpretation involved long term malignancies Measures Musculoskeletal Protective rituximab SARS-CoV-2 SARS-COV-2 infection serological significantly Therapeutic approach therapeutic strategy vaccine responses variety [DOI] 10.3389/fimmu.2021.763412 PMC 바로가기 [Article Type] Review
Efficacy of convalescent plasma therapy in immunocompromised patients with COVID-19: A case reportCase report Published on 2021-11-012022-10-05 Journal: Clinical Infection in Practice [Category] 변종, 임상, [키워드] absence Acquired antibody B-cell lymphoma Case report CCP CCP administration characteristic clinical clinical evaluation cohorts of patient Complete component convalescent plasma Convalescent plasma therapy Course COVID-19 COVID-19 patient Cytopathic effect effective Effectiveness Evidence female finding help hospital discharge Hospitalization Host host response Hypogammaglobulinemia immune immune deficiency immune response Immunocompromised Immunocompromised patient individuals infused inhibiting interstitial pneumonia mechanism Neutralizing antibodies nucleotide Patient performed plasma radiological finding reduce Remdesivir required Research Result rituximab SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 replication selected severe COVID-19 sustained Symptom T-cell specific tested treated Treatment viral clearance viral culture Viral load virus [DOI] 10.1016/j.clinpr.2021.100096 [Article Type] Case report
[Are SARS-CoV-2 reactive T cells detectable and potentially protective in patients under anti-CD20 treatment with an impaired humoral response?][SARS-CoV-2 반응성 T 세포는 체액성 반응이 손상된 항-CD20 치료를 받는 환자에서 감지 가능하고 잠재적으로 보호 가능한가요?]Article Published on 2021-11-012022-09-11 Journal: Zeitschrift Fur Rheumatologie [Category] SARS, 치료기술, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 anti-CD20 treatment antibody formation B cell cellular Cellular and humoral immunity Cellular immune response changed chronic inflammatory disease chronic inflammatory diseases Contact coronavirus coronavirus disease Coronavirus disease 2019 country COVID-19 depleting detectable effective English fatality framework Gut humoral Humoral immunity immune system Immunosuppression Infection Inflammatory diseases less life Masks monoclonal antibody obligatory organ Organ transplant pandemic pathogen Patient patients treated Probability Protective reactive recent Rheumatic diseases risk rituximab RTX SARS-CoV-2 SARS-CoV‑2 SARS-CoV‑2 vaccination. severe acute respiratory syndrome Coronavirus severity Spread T cell vaccination Vaccinations virus Welt [DOI] 10.1007/s00393-021-01083-3 PMC 바로가기 [Article Type] Article
Severe autoimmune hemolytic anemia following receipt of SARS-CoV-2 mRNA vaccineSARS-CoV-2 mRNA 백신 접종 후 중증 자가면역 용혈성 빈혈Case Reports Published on 2021-11-012022-09-11 Journal: Transfusion [Category] MERS, SARS, 진단, 치료기술, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 administer anti-IgG antiglobulin reagent antiglobulin test Autoimmune autoimmune hemolytic anemia blind clinical trial clinician coronavirus Corticosteroids demonstrated detect Diagnosis Direct antiglobulin test direct antiglobulin test. effort first dose hemolytic anemia IgG IgG isotype IgG isotypes immune immune globulin Immune thrombocytopenia Immunoglobulin initial isotypes life-threatening mRNA mRNA vaccine mycophenolate mycophenolate mofetil myocarditis Patient positive reagents red blood cells required respiratory rituximab SARS-CoV-2 SARS-CoV-2 mRNA vaccine SARS-CoV-2 vaccine SARS-CoV-2 vaccines severe acute respiratory syndrome Coronavirus Therapies thrombocytopenia thrombotic Thrombotic thrombocytopenia transfusion Treatment Vaccine [DOI] 10.1111/trf.16672 PMC 바로가기 [Article Type] Case Reports
Antibody responses to the SARS-CoV-2 vaccine in individuals with various inborn errors of immunity다양한 선천성 면역 오류가 있는 개인의 SARS-CoV-2 백신에 대한 항체 반응Article Published on 2021-11-012022-09-11 Journal: The Journal of Allergy and Clinical Immunology [Category] MERS, SARS, 진단, 치료법, [키워드] adverse event adverse events affected age anti-S anti-S IgG anti-S IgG levels antibody Antibody Response Antibody titer Antibody titers Autoimmune B cells B-cell baseline candidiasis Care CD19 CD3 Cohort cohort of patient completion controls counseling COVID-19 COVID-19 vaccine Diagnosis dose evaluate Genetic Health Health care immune immune suppressants Immunity immunization immunization schedule immunized immunogenicity immunomodulators immunosuppressive drug immunosuppressive drugs Inborn errors inborn errors of immunity individual information Jak jak inhibitors janssen Johnson & Johnson less luciferase Luciferase immunoprecipitation system median medical records mRNA vaccine Patient patients plasma rate of seroconversion reported rituximab Safe SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 vaccination second dose Seroconversion single dose subsequent T cells the SARS-CoV-2 therapy These data thymoma Treatment Vaccinating Vaccine was collected were measured [DOI] 10.1016/j.jaci.2021.08.016 PMC 바로가기 [Article Type] Article
The Outcome of COVID-19 in Patients with a History of Taking Rituximab: A Narrative Review리툭시맙 복용 이력이 있는 환자의 COVID-19 결과: 내러티브 검토Review Published on 2021-11-012022-09-12 Journal: Iranian journal of medical sciences [Category] 진단, [키워드] addressed appear Autoimmune disease caused CD20 Clinical course Concomitant medication coronavirus 2 Coronavirus disease 2019 Course COVID-19 Diseases Efficacy emerging disease history immune system diseases Immunosuppressive medication increased risk indicated Infection infections Infectious disease malignancies monoclonal antibody morbidity and mortality narrative pandemic Patient patients patients with SARS-CoV-2 previous study receiving respiratory review rituximab RTX SARS-CoV-2 Taking the disease Treatment underlying disease Vaccine [DOI] 10.30476/IJMS.2021.88717.1946 PMC 바로가기 [Article Type] Review
Impact of rituximab on COVID-19 outcomesCOVID-19 결과에 대한 리툭시맙의 영향Article Published on 2021-11-012022-09-12 Journal: Annals of Hematology [Category] MERS, SARS, 진단, [키워드] administration Admission Analysis Anti-spike antibodies antibody B-cell B-lymphocytes baseline characteristics checked Clinical outcome clinical outcomes conducted COVID-19 COVID-19 antibody COVID-19 diagnosis death diagnosed with COVID-19 died disease severity examined Hospitalization humoral Humoral immunity Hypogammaglobulinemia ICU admission Impact Infectious complications intensive care unit marker median time Mount Sinai Neutralizing neutralizing antibody not affect not significantly different outcome over Patient Protein required Retrospective study rituximab SARS-CoV-2 SARS-COV-2 infection survived System T-cell immunity therapy [DOI] 10.1007/s00277-021-04662-1 PMC 바로가기 [Article Type] Article
Abatacept is second to rituximab at risk of HBsAg reverse seroconversion in patients with rheumatic diseaseArticle Published on 2021-11-012023-06-13 Journal: Annals of the rheumatic diseases [Category] B형 간염, [키워드] abatacept rituximab Tumour necrosis factor inhibitors [DOI] 10.1136/annrheumdis-2021-220774
Effect of Immunosuppressive Diseases and Rituximab Infusions on Allowing COVID-19 Infection to RelapseCOVID-19 감염의 재발을 허용하는 면역억제성 질환 및 리툭시맙 주입의 효과Case Reports Published on 2021-10-292022-09-12 Journal: The Permanente journal [Category] MERS, 진단, [키워드] addition antibodies B-cell case sery convalescent plasma COVID-19 COVID-19 infection COVID-19 vaccine decrease disease course Effect Effectiveness etiology immunosuppressed patients Immunosuppression induce Infection infusion initial laboratory investigation medications Patient receive Relapse relapsing reported rituximab severity the patient the vaccine [DOI] 10.7812/TPP/21.035 PMC 바로가기 [Article Type] Case Reports
Pemphigus—The Crux of Clinics, Research, and Treatment during the COVID-19 PandemicReview Published on 2021-10-282022-10-28 Journal: Biomedicines [Category] COVID-19, [키워드] approach autoantibody autoantigen Autoimmune disease Blister classical clinics COVID-19 COVID-19 infection desmoglein determine develop diagnostic discrepancy immunodermatology immunosuppressive effect lesion Manifestations mucosal other immunosuppressive agents Pathogenesis pathogenic autoantibody pathophysiological Patient pemphigus profile Proteins raised risk rituximab SARS-CoV-2 SARS-CoV-2 pandemic subtype Treatment use of corticosteroid vaccine response variant [DOI] 10.3390/biomedicines9111555 PMC 바로가기 [Article Type] Review